Get Started
Multiple Sclerosis Curricula
Step 1



The Advanced Certificate Program in
Multiple Sclerosis Management III
  1. Curriculum VI
  2. Curriculum V
  3. Curriculum IV
  4. Curriculum III
  5. Full Course List
CME/CE Information

Target Audience

This series of activities is designed for neurologists and primary care physicians (including family practice, internists, and general practitioners), as well as nurses and pharmacists, who manage and treat patients with multiple sclerosis.

Activity Goal

The goal of these CME/CE activities is to examine current and emerging strategies for diagnosing, treating, and managing patients with multiple sclerosis.

Learning Objective (s)

  • Assess the etiology, pathophysiology, and diagnosis of MS in order to determine appropriate treatment approaches that improve patient outcomes.
  • Apply knowledge of current and emerging imaging technologies, including MRI, to diagnose, monitor intervention, and determine disease progression to formulate and improve treatment strategies for patients with MS.
  • Evaluate the immune and inflammatory response in MS, potential targets for therapeutic intervention, and the molecular complexity of MS therapies that affect their safety and efficacy to select optimal therapies and strategies for the treatment of MS patients.
  • Assess and differentiate across current and emerging MS therapies based on an understanding of MOA, safety, and efficacy to develop optimal treatment strategies that improve patient outcomes.
  • Evaluate long-term efficacy and safety of MS therapies with regard to disability (EDSS, MSSS, MSFC), QOL, pharmacoeconomics and patient outcomes.
  • Customize therapies for MS patients based on an understanding of their form of MS, symptoms, concomitant medications, comorbidities, and compliance, to improve their response.


CME Information: Physicians


Statement of Accreditation

Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge® designates this educational activity for a maximum of 18.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE Information: Nurses

Specific credit information can be found on each activity's web page.

CE Information: Pharmacists

Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

CME/CE Instructions


To obtain CME/CE credit:

  1. Read or listen to each activity carefully.
  2. Complete/submit each posttest and evaluation.
  3. Instantly access and print out your certificate.

There is no fee for this activity.

CONTRACT FOR MUTUAL RESPONSIBILITY IN CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here.
Disclosure Information

The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Fred D. Lublin, MD has conducted contracted research for Acorda Therapeutics, Biogen Idec, Genentech, Inc, Genzyme, NIH, NMSS, Novartis Pharmaceuticals Corporation, Sanofi-aventis, and Teva Neuroscience; has received consulting fees from Acorda Therapeutics, Actelion Pharmaceuticals, Allozyne, Avanir Pharmaceuticals, Bayer HealthCare, Biogen Idec, BioMS Medical Corp, EMD Serono, Genentech, Inc, Genmab, MediciNova, Novartis Pharmaceuticals Corporation, Pfizer, Questcor Pharmaceuticals, Roche, Sanofi-aventis, and Teva Neuroscience; is on the speakers bureau for EMD Serono, Pfizer, and Teva Neuroscience; and has an equity interest in Cognition Pharmaceuticals, Inc.

Aaron E. Miller, MD has conducted contracted research for Acorda Therapeutics, Biogen Idec, Genentech, Inc, Genzyme, Novartis Pharmaceuticals Corporation, Sanofi-aventis, and Teva Neuroscience; has received consulting fees from Acorda Therapeutics, Biogen Idec, BioMarin, Daiichi Sankyo, EMD Serono, GlaxoSmithKline, Merck Serono, Novartis Pharmaceuticals Corporation, ONO, Sanofi-aventis, and Teva Neuroscience; and is on the speakers bureau for Acorda Therapeutics, Biogen Idec, EMD Serono, Pfizer Inc, and Teva Neuroscience.

Anne H. Cross, MD has received salary/honoraria from Bayer Healthcare, Biogen Idec, Quintiles, and Teva Neuroscience; has received consulting fees from Bayer Healthcare, Biogen Idec, Hoffmann-La Roche, sanofi-aventis, and Teva Neuroscience; has conducted contracted research for Acorda Therapeutics, Hoffmann-La Roche, and sanofi-aventis.

Tracy M. DeAngelis, MD is on the speakers bureau for EMD Serono.

Suhayl Dhib-Jalbut, MD has received salary/honoraria from, has received consulting fees from, and has conducted contracted research for Bayer HealthCare, Biogen Idec, EMD Serono, and Teva Neuroscience.

Robert P. Lisak, MD, FRCP, FAAN, FANA has received honoraria from Bayer HealthCare and Teva Neuroscience; has received consulting fees from Avanir Pharmaceuticals, Questcor Pharmaceuticals, Sanofi-aventis, and Teva Neuroscience; and has conducted contracted research for Biogen Idec, Genentech, Inc, Genzyme Corporation, Questcor Pharmaceuticals, Teva Pharmaceuticals, and Teva Neuroscience.

Alberto Ascherio, MD, DrPH has received honoraria from Wayne State University, New York University School of Medicine, and Buffalo Neuroimaging Analysis Center (BNAC).

James D. Bowen, MD has received honoraria from Berlex, Inc., Biogen Idec, EMD Serono Inc., and Teva Neurosciences; has received financial support for research from Biogen Idec, BioMS Medical, EMD Serono, Genzyme Corporation, Novartis Pharmaceuticals Corporation, and UCB S.A. and has ownership interest in Amgen Inc.

David A. Hafler, MD

Matilde Inglese, MD, PhD has received salary/honoraria from EMD Serono.

Augusto A. Miravalle, MD has received salary/honoraria from Bayer Health Care, Biogen Idec, and Questcor Pharmaceuticals; has received consulting fees from Bayer HealthCare, Biogen Idec, Questcor Pharmaceuticals and Teva Neuroscience; and is on the speakers bureau for EMD Serono and Teva Neuroscience.

Peer Reviewer has disclosed no significant relationships.

Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.

Projects In Knowledge's staff members have no significant relationships to disclose.

These activities may contain discussions of unlabeled/unapproved uses of drugs or devices. Specific product disclosure will be forthcoming in each activity.

The opinions expressed in these activities are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

1946